SCHEMBL602155

SCHEMBL602155

CCOC(=O)c1ccc(C2CCC(CCC(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.48
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ESR1 P03372 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
ESR2 Q92731 1/20 0.41
CA14 Q9ULX7 1/20 0.41
FDFT1 P37268 1/20 0.41
CYP19A1 P11511 2/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL602156 1.00 CYP2C9 (0.48) CYP2C9MAPTLMNAALDH1A1RAB9A
SCHEMBL601321 0.89 CYP2C9 (0.46) CYP2C9MAPTLMNAALDH1A1RAB9A
SCHEMBL601291 0.85 CYP2C9 (0.49) CYP2C9MAPTLMNAALDH1A1ESR2
SCHEMBL601290 0.85 CYP2C9 (0.49) CYP2C9MAPTLMNAALDH1A1ESR2
SCHEMBL14973695 0.84 CYP2C9 (0.65) CYP2C9MAPTLMNAALDH1A1ESR2
SCHEMBL14973696 0.84 CYP2C9 (0.65) CYP2C9MAPTLMNAALDH1A1ESR2
SCHEMBL17730783 0.82 CYP2C9 (0.46) CYP2C9MAPTLMNAALDH1A1RAB9A
SCHEMBL4003420 0.82 CA12 (0.59) CYP2C9MAPTLMNAALDH1A1RAB9A
SCHEMBL602055 0.81 RAB9A (0.50) CYP2C9MAPTLMNAALDH1A1RAB9A
SCHEMBL10188594 0.81 RAB9A (0.50) CYP2C9MAPTLMNAALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546391-B2 Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-10-01 US disclosed
CN-102365273-A Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof SANOFI AVENTIS 2012-02-29 CN disclosed
US-20120040984-A1 THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040984-A1 THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF OXA1L, CYP11B2, CYP11B1 CYP2C9 64/4885MAPT 2666/4885LMNA 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.